Riskpilot← Back to searchSign inGet full accessBIOMED PHARMA AS
ASActiveOrg 996893626Karoline Kristiansens Vei 2, 0661 OsloPostordre-/Internetthandel med helsekost · NACE 47917Est. 20110 employees
Revenue 2021
NOK 109,2M
-1% vs 2020
EBITDA margin
35.6%
-14% vs 2020
Equity ratio
2.1%
Financial strength
Net profit 2021
NOK 30,5M
-14% vs 2020
| Revenue | NOK 109,2M | -1% |
| EBITDA | NOK 38,9M | -14% |
| Net profit | NOK 30,5M | -14% |
| Total assets | NOK 57,5M | +89% |
| Equity | NOK 1,2M | -79% |
| Employees | 0 | — |
Legal name
BIOMED PHARMA AS
Org number
996893626
Legal form
Aksjeselskap
NACE code
47917 · Postordre-/Internetthandel med helsekost
Founded
18. mai 2011
Share capital
NOK 10 000 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Virksomhet innen direktehandel, samt annen virksomhet som naturlig faller inn under dette, herunder deltakelse i andre selskaper.
Address
Karoline Kristiansens Vei 2, 0661 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue | 103 004 | 130 010 | 123 453 | 110 656 | 109 223 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 36 555 | 42 666 | 45 174 | 45 169 | 38 896 |
| Depreciation & amort. | −0 | −150 | −221 | −244 | −233 |
| EBIT | 36 555 | 42 516 | 44 953 | 44 924 | 38 664 |
| Net financials | 41 | 32 | 179 | 581 | 425 |
| Profit before tax | 36 596 | 42 548 | 45 132 | 45 505 | 39 088 |
| Tax | 8 234 | 9 801 | 9 933 | 10 026 | 8 602 |
| Net profit | 28 362 | 32 747 | 35 199 | 35 479 | 30 487 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Total assets | 36 936 | 41 371 | 35 204 | 30 371 | 57 530 |
| Equity | 501 | 501 | 14 300 | 5 780 | 1 233 |
| Long-term debt | 465 | 0 | 0 | 0 | 0 |
| Short-term debt | 35 971 | 40 870 | 20 904 | 24 591 | 56 296 |
| Total debt | 36 435 | 40 870 | 20 904 | 24 591 | 56 296 |
EBITDA margin
35.6%
This company
15.8%
Market median
+125% vs market
20172021
Equity ratio
2.1%
This company
38.2%
Market median
-95% vs market
20172021
Return on equity
2472.5%
This company
18.4%
Market median
+13338% vs market
20172021
Net profit margin
27.9%
This company
8.1%
Market median
+244% vs market
20172021
Asset turnover
1.90×
This company
1.12×
Market median
+70% vs market
20172021
Debt / equity
45.66×
This company
0.62×
Market median
-7265% vs market
20172021
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Former (1) | ||
| Chairman | 2019 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BIOMED PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Geert Cools | Board of Directors | 0 companies |
| Bernard Jean Y Lemaire | Chairman | 0 companies |
| Rikard Arne Storvestre | Chairman | 0 companies |